Introduction {#Sec1}
============

Infectious bronchitis virus (IBV) is a Gamma coronavirus that causes a highly contagious disease in chickens (Cavanagh [@CR4]). The virus causes severe economic losses to the poultry industry worldwide because it can affect the upper respiratory and reproductive tracts, and some strains can cause nephritis in chickens (Lim et al. [@CR14]). IBV genome consists of positive-stranded RNA, with 27.6 kb in length. The 3′ end of IBV genome is approximately 7.0 kb in length and encodes four structural proteins, of which the spike protein (S), localized on the IBV particle surface, is composed of two subunits, namely, S1and S2 (Huo et al. [@CR11]). The S1 subunit, located on the outside of virion, is responsible for the fusion between the virus envelope and the cell membrane of the host (Jackwood [@CR12]). Different serotypes have been reported worldwide, and new variant serotypes continue to be recognized (Jackwood [@CR12]). In September 1997, an outbreak of the disease (QX outbreak), characterized mainly by swelling of the stomach (Proventriculitis), diarrhea, and loss of body weight in 25- to 70-day-old chickens occurred in chicken flocks in Qingdao, China (Wang et al. [@CR20]). However, it was not recognized as a novel type of IBV at that time (Liu and Kong [@CR15]). Bozorgmehri-Fard et al. ([@CR2]) have demonstrated the presences of QX viruses in Iranian commercial flocks, and after this outbreak, many false layers were reported in Iran. If the QX enters to flock before 10 days old, it causes a permanent effect on oviduct lead to blind layers. As QX vaccine does not have a permit to use in Iranian flock, just Massachusetts and 793/B-like vaccines are being used (Bozorgmehri-Fard et al. [@CR2]). Currently, the rate of QX in Iranian flocks is around 8% and is reported from several countries (Hosseini et al. [@CR10]). Several strains have been developed as vaccines strains, including IBV vaccine strains H120, M41, and 793/B. Since IBV is epidemic in both industrial and backyard chickens, flocks are vaccinated from birth with either attenuated live or inactivated IBV. The IBV H120 strain, an attenuated live vaccine strain of the Massachusetts (Mass) type, is widely available and reliable vaccine strain that is used as a primary vaccine in broilers, breeders, and future layers. Also, several 793/B type vaccines (793/B; IB88; 1/96) are using as IB vaccine in combination with Mass type (Yang et al. [@CR22]). The most usual approach for protection of flocks for most IBV genotypes is using heterologous vaccines for example Mass (1 day old) and 793/B type (12--14 days old) vaccines against QX. The aim of this study is to evaluate the different vaccination programs against QX challenge.

Materials and method {#Sec2}
====================

Experimental design {#Sec3}
-------------------

White specific pathogen-free (SPF) leghorn chickens were divided into four groups containing 20 birds each. Each group in all experiments was kept in a separate negative pressure isolators. They were provided with food and water ad libitum. Groups were vaccinated and challenged as shown in Table [1](#Tab1){ref-type="table"}. Groups 1 and 2 were kept as negative control (non-vaccinated, non-challenged) and positive control (non-vaccinated-challenged group), respectively. The chicken in groups 3 and 4 were vaccinated with Mass (H120; Ceva Sante Animale) and 793/B vaccines (4/91; Intervet), in two programs using an eye drop. Group 3 received H120 and 793/B vaccines in days 1 and 14, respectively. In group 4, chickens were vaccinated with H120 in day 1 and H120+793/B in day 14. Thirty-five days post rearing, chickens were challenged using nasal route (104 EID50). Before challenging, sera samples were taken from the birds to evaluate ELISA titers of IBV vaccination using IDEXX kit (IDEXX Laboratories, Inc., USA). Five days after challenge, samples were taken from trachea and kidneys for histopathology, quantitative real-time RT-PCR, and cilliary activity of the trachea. The challenge virus was isolated from commercial broiler farm. Homogenized samples were inoculated into 9--11 embryonated SPF eggs. Primary diagnosis of the IBV was done using 5′-UTR in PCR test. The QX virus was selected and passaged in SPF egg. Challenge virus was tested in nested RT-PCR and S1 gene was sequenced and submitted to NCBI (accession no. KT583570.1). It was shown to be free from contamination by other avian pathogens such as Newcastle disease virus, avian influenza virus, infectious laryngotracheitis virus, reovirus, mycoplasma, and other bacteria using molecular detection methods and cultivation. EID50 was calculated by the Reid--Muench method.Table 1Experimental schedule of vaccination using H120 and 793/B vaccines and challenge with QX-like IBV 21 days post last vaccinationGroup no.Names of groupsDay 1Day 14Challenge (day 35)ELISA (IDEXX) (day 35)Ciliostasis scoreTrachea viral loadKidney viral load1Non-vaccinated------0.00E+00^c^0.00E+00^d^0.00E+00^d^0.00E+00^d^2Non-vaccinated-challenged group----+0.00E+00^c^39.6 ± 0.4^a^2.97E+05^a^3.65E+04^a^3H120-793/BH120793/B+1007 ± 147.9^a,b^7.25 ± 1.23^b^2.55E+03^b^2.76E+01^b^4H120+793/B--793/BH120+793/B793/B+1248.55 ± 152.34^a^7.05 ± 1.71^bc^2.52E+02^bc^1.01E+01^bc^ELISA titer, ciliostasis score, tracheal viral load, and kidney viral load are shown in all groups^a,b,c,d^ There was a non-significant difference (*P* ≤0.05) between the non-vaccinated-challenged group with vaccinated groups

Quantitative real-time RT-PCR {#Sec4}
-----------------------------

Viral RNA was isolated from tissues using Cinna PureRNA extraction kit (Sinaclone, Iran) according to the suppliers' instructions. cDNA was synthesized using Revert Aid first-strand cDNA synthesis kit (Thermo Scientific, Canada). Real-time PCR for IBV detection based on 5′-UTR was used in this study. Real-time PCR amplification was done with the amplification kit (Bioneer, South Korea) with a forward primer (5′-GCTTTTGAGCCTAGCGTT-3′) and reverse primer (5′-GCCATGTTGTCACTGTCTATTG-3′) and *Taqman* dual-labeled probe (FAMCACCACCAGAACCTGTCACCTC-BHQ1) (Callison et al. [@CR3]). The 5′ UTR of M41reference IBV strain and 28s rRNA of chick tissue were amplified using the same primers applied in real-time PCRreaction. The PCR products were examined using agarose gel electrophoresis. After ethidium bromide staining, the bands were visible only at the expected molecular weights (a 143-bp fragment for 5′-UTR of M41 and 61-bp fragment for 28srRNA). The PCR products for 5′-UTR and 28s rRNA were cloned in a pTG19-T vector and transformed in *Escherichia coli* TOP10 competent cells. Plasmid isolation kit mini-preparation (molecular biological system transfer, Tehran, Iran) was used to extract plasmids. Before use, the plasmid concentration was determined by spectrophotometry at 260 nm and calculated as genomeequivalents (copies) per milliliter as the molecular weight of the plasmid was known. Serial dilutions were performed togive a final concentration between 102 and 105 (for 5′-UTR) and 102 and 105 (for 28s rRNA) copies for generating the standard curves (Najafi et al. [@CR17]).

Histopathology {#Sec5}
--------------

Five days post challenge, the chickens were euthanized and trachea and lung and kidney were collected and transferred to 70% buffered formalin. Tissue samples were stained using hematoxylin and eosin staining method.

Ciliostasis test {#Sec6}
----------------

Assessment of protection against challenge each experiment was evaluated using ciliostasis test. The tracheas were carefully removed and examined for ciliary activity as described previously. Briefly, each of ten tracheal rings (three rings of upper, four rings of middle, and three rings of lower trachea) was examined by low-power microscopy and ciliary activity was evaluated as follows: 0 = all cilia beating;1 = 75% beating; 2 = 50% beating; 3 = 25% beating; and 4 = none beating (100% ciliostasis). This gave a maximum possible ciliostasis score of 40 in case of complete ciliostasis.

Statistical analysis {#Sec7}
--------------------

To evaluate and compare the ciliostasis between the groups, Mann--Whitney test using GraphPad Prism 7.0 software was used. The 0.05 level was considered as significant. Finally, one-way ANOVA with a significance level of 0.05 was used to compare viral loads.

Results {#Sec8}
=======

IBV antibody {#Sec9}
------------

The titer of antibody against IBV was measured by ELISA method for evaluating the efficacy of vaccination program on the response of the immune system. No significant difference (*P* \> 0.05) was found in mean titer between groups 3 (1007 ± 147.9) and 4 (1248.55 ± 152.34), and no antibody was observed in non-vaccinated-challenged group and negative control group (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean titter of antibody against IBV in different groups (IDEXX; ELISA)

Protection rate and ciliostasis score {#Sec10}
-------------------------------------

Based on the results of the ciliostasis test, the cross-protection rate for the the vaccinated groups 3 and 4 is 81% and 84% at 5 days post challenge (Fig. [2](#Fig2){ref-type="fig"}). No protection was observed in non-vaccinated group after challenge. The ciliostasis score of group 4 (7.05 ± 1.71) was lower that group 3 (7.25 ± 1.23) (non-significant; *P* \> 0.05) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2The protection rate against QX genotype with different vaccination programsFig. 3The ciliostasis score against QX genotype with different vaccination programs

Quantitative real-time RT-PCR {#Sec11}
-----------------------------

Viral load in trachea and kidney was counted by quantitative Real-time RT-PCR. Results are shown in (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). In trachea, significant difference (*P* \< 0.05) was detected comparing the non-vaccinated-challenged group with H120-793/B and H120+793/B--793/B groups but no significant difference was observed between H120-793/B and H120+793/B--793/B groups (Fig. [4](#Fig4){ref-type="fig"}). Kidney sample viral load between H120-793/B group and the non-vaccinated-challenged group showed a significant difference (*P* \< 0.05), and a similar result was observed comparing vaccinated group together (*P* \< 0.05) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4The tracheal vial load of QX genotype with different vaccination programsFig. 5The kidney vial load of QX genotype with different vaccination programs

Histopathological assessment {#Sec12}
----------------------------

Relative protection was observed in vaccinated groups by evaluation of lung histopathological tissue between challenged groups. The non-vaccinated-challenged group showed that histopathological findings include hyperemia, infiltration of inflammatory cells into interstitial tissue cells. In vaccinated H120--793/B group and H120+793/B--793/B group, mild hyperemia and mild infiltration of inflammatory cells in interstitial tissue were observed, respectively (Fig. [6](#Fig6){ref-type="fig"}). Trachea histopathological showed the similar result as in the lungs. Hyperemia, infiltration of inflammatory cells to interstitial tissue cells and degeneration of epithelial cells were recorded in the non-vaccinated-challenged group, whereas in vaccinated groups, mild hyperemia and mild infiltration of inflammatory cells in interstitial tissue were observed (Fig. [7](#Fig7){ref-type="fig"}). In kidney inflammatory cells, predominantly mononuclear cells, hyperemia, and hemorrhage were observed in the non-vaccinated-challenged group. In other groups, no abnormal lesion was detected (Fig. [8](#Fig8){ref-type="fig"}).Fig. 6Histopathology of the trachea tissue changes of the hematoxylin and eosin-stained trachea infected with QX-like isolate. **a** Tracheal lesion of non-vaccinated-challenged group shows hyperemia and infiltration of inflammatory cell to interstitial tissue cells. **b** H120-793/B-vaccinated group with mild hyperemia in trachea. **c** H120+793/B--793/B-vaccinated group shows a mild infiltration of inflammatory mononuclear cells in parenchymaFig. 7Histopathology of the lung. Tissue changes of the hematoxylin and eosin-stained lung infected with QX-like isolate. **a** Lung lesion of non-vaccinated-challenged group shows hyperemia and infiltration of mononuclear inflammatory cell to interstitial tissue cells. **b** H120-793/B-vaccinated group with mild hyperemia in the lung. **c** H120+793/B--793/B-vaccinated group shows no lesion to a mild infiltration of inflammatory mononuclear cells in parenchymaFig. 8Histopathology of the kidney. Tissue changes of the hematoxylin and eosin-stained kidney infected with QX-like isolate. **a** Kidney lesion of non-vaccinated-challenged group shows and infiltration of mononuclear inflammatory cell to interstitial tissue cells focally, hyperemia and focal hemorrhages. **b** H120-793/B-vaccinated group with hyperemia in the lung. **c** H120+793/B--793/B-vaccinated group shows no lesion

Discussion {#Sec13}
==========

The first infectious bronchitis infection (IB) was reported in Iran in 1994. Today, five IBV genotypes are circulating in Iranian chicken flock including Mass, 793/B-like, IS/1494-like, QX-like, and D274 based on their hypervariable S1 gene sequencing studies (Hosseini et al. [@CR10]; Najafi et al. [@CR18]). Bozorgmehri-Fard et al. have isolated QX genotype in 2011. In an epidemiological study, it has been reported that QX virus is the third dominant IBV circulating in Iranian poultry farms (Modiri Hamadan et al. [@CR16]). Today, Ma5, H120, and 793/B vaccines are available and are being used in a different program in the region and most of countries. Vaccination by one serotype does not make a sufficient immunity against heterologous virus; therefore, multivaccination program by a combination of different serotypes is suggested (Cook et al. [@CR6]; Gelb et al. [@CR8]).

In this study, we have chosen a combination of Mass (H120) and 793/B serotype in two programs. Several clinical studies have revealed that using of two or more attenuated IBV live vaccines could make a vast protection immunity against heterologous serotype (Cook et al. [@CR6]). A study by De Wit et al. ([@CR7]) revealed that combination of Mass (day 1) + 793/B (day 14) vaccines, and challenge with D388 (QX genotype) on day 28th in commercial broiler breeder, could make 51% and 74% protection in ciliostasis test on 5 and 7 days post challenge, respectively (de Wit et al. [@CR7]). In the present study, the chicken received the vaccine by eye drop administration based on a suggestion by Cook et al. (Cook et al. [@CR6]). In the present study, vaccinated group 4 (day 1: H120+793/B and day 14: 793/B) showed higher ciliostasis protection (84%) in comparison to vaccinated group 3 (day1: H120 and day14: 793/B) with 81% of protection; the difference was not significant, however. It has been concluded that combination of two serotypes at day 1 could induce a significant increase in expression of CD+, CD8, and IgA-bearing B cell in comparison to single H120 vaccination that leads to higher level of cellular and local immunity at the trachea (Awad et al. [@CR1]; Lambrechts et al. [@CR13]). It should be kept in mind that in the best condition in the cross-protection experiment, 10% of vaccinated bird would not present sufficient immunity even against homologous strain (Winterfield et al. [@CR21]), demonstrating that chickens are different in response to IBV vaccination. In our study, group 4 showed a higher antibody in day 35 demonstrating better protection in internal organs facing IBV strain. It has been proved that cytotoxic T cells are the major blood cells protecting the body in the early stage of IBV infection and IgG circulating in blood serum support the internal organs including ovaries and oviduct in the later stage of the disease (Collisson et al. [@CR5]; Raj and Jones [@CR19]). The essential issue in IBV infection is to protect trachea from virus lesions. The inconvenient situation in the house including high ammonia, dust, CO~2~, and another microorganism in the air would make the condition worse (Habibi et al. [@CR9]). In the present study, the vaccinated groups 3 and 4 showed a slight lesion in the trachea in comparison to the no-vaccinated-challenged group. In the positive control group, the lesion such as hyperemia, significant infiltration of inflammatory cells in interstitial tissue, and degeneration of epithelial cells in trachea demonstrating the severity of our QX-like virus. Furthermore, it is proved that both vaccination programs could reduce the IBV lesion in the trachea. Due to widespread and continuous changes in IBV and emergence of new variant, making of new vaccine for each variant is not economically possible; therefore, the solution facing with new variant is to apply available commercial vaccine in a program to make broad cross-protection against these new viruses. The emergence of new IBV variant named QX has caused several problems in poultry flocks specially layers and breeders. It should be noted that in farm situation, drinking water vaccination is the preferred method usually done by the farmer and as long as this method is not as efficient as eye drop, using H120+793/B at day 1 could make better protection. Furthermore, higher antibody titer protects the kidney, oviduct, and internal organs facing the disease. However, further studies are needed to investigate other vaccination program to control IBV infections in Iranian poultry farms.

Conclusion {#Sec14}
==========

According to our investigation, both vaccination programs (day 1: H120, day 14: 793/B and day 1: H120+793/B, day 14: 793/B) induced significant protection against QX challenge; however, higher protection, lower QX viral load in trachea and kidney, and fewer ciliostasis score were recorded using 793/B vaccine in combination with H120 at day 1.
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